Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction in heart failure.

Recent evidence suggests the possibility that enhanced inactivation of endothelium-derived nitric oxide (NO) by oxygen free radical (OFR) may cause endothelial dysfunction in heart failure (HF). To test this hypothesis, we examined the effect of antioxidant therapy on endothelium-dependent vasodilation of the coronary circulation in a canine model of tachycardia-induced HF. Endothelium-dependent vasodilation was less than that in controls, and OFR formation in coronary arterial and myocardial tissues was greater in HF dogs than those in controls. The immunohistochemical staining of 4-hydroxy-2-nonenal, OFR-induced lipid peroxides was detected in coronary microvessels of HF dogs. Intracoronary infusion of the cell-permeable OFR scavenger Tiron inhibited OFR formation and improved endothelium-dependent vasodilation in HF dogs but not in controls. The NO synthesis inhibitor N(G)-monomethyl-L-arginine (L-NMMA) diminished the beneficial effect of Tiron in HF dogs. Endothelium-independent vasodilation was similar between control and HF dogs, and no change in its response was noted by Tiron or Tiron plus L-NMMA in either group. In summary, antioxidant treatment with Tiron improved coronary vascular endothelium-dependent vasodilation by increasing NO activity in tachycardia-induced HF. Thus coronary endothelial dysfunction in HF may be, at least in part, due to increased inactivation of NO by OFR.

[1]  A. Takeshita,et al.  Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. , 2000, Circulation research.

[2]  L. Kuo,et al.  LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. , 1998, Circulation research.

[3]  D. Chatel,et al.  Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. , 1998, Circulation.

[4]  J. Kjekshus,et al.  Elevated circulating levels of C-C chemokines in patients with congestive heart failure. , 1998, Circulation.

[5]  H. Drexler,et al.  Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.

[6]  R. Bonow,et al.  Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.

[7]  P. Stiegler,et al.  Pacing-induced heart failure in dogs enhances the expression of p53 and p53-dependent genes in ventricular myocytes. , 1998, Circulation.

[8]  D. Harrison,et al.  Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.

[9]  P. Singal,et al.  Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. , 1997, Circulation.

[10]  I. Fridovich Superoxide Anion Radical (O·̄2), Superoxide Dismutases, and Related Matters* , 1997, The Journal of Biological Chemistry.

[11]  A. Takeshita,et al.  Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. , 1997, Hypertension.

[12]  A. Takeshita,et al.  Role of Myocyte Nitric Oxide in β-Adrenergic Hyporesponsiveness in Heart Failure , 1997 .

[13]  M. Redfield,et al.  Angiotensin II in the evolution of experimental heart failure. , 1996, Hypertension.

[14]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Stadtman,et al.  Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. , 1995, Archives of biochemistry and biophysics.

[16]  P. Anversa,et al.  The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. , 1995, Circulation.

[17]  A. Takeshita,et al.  Glibenclamide, a selective inhibitor of ATP-sensitive K+ channels, attenuates metabolic coronary vasodilatation induced by pacing tachycardia in dogs. , 1995, Circulation.

[18]  S. Katz The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. , 1995, Progress in cardiovascular diseases.

[19]  A. Takeshita,et al.  Effects of L‐Arginine on Impaired Acetylcholine‐Induced and Ischemic Vasodilation of the Forearm in Patients With Heart Failure , 1994, Circulation.

[20]  X. Xu,et al.  Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. , 1994, The American journal of physiology.

[21]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[22]  S. Hahn,et al.  The catecholic metal sequestering agent 1,2-dihydroxybenzene-3,5-disulfonate confers protection against oxidative cell damage. , 1992, Archives of biochemistry and biophysics.

[23]  J. Belch,et al.  Oxygen free radicals and congestive heart failure. , 1991, British heart journal.

[24]  M. Wolin,et al.  Superoxide anion inhibits cGMP-associated bovine pulmonary arterial relaxation. , 1990, The American journal of physiology.

[25]  R D Fish,et al.  Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. , 1990, Circulation.

[26]  A. Takeshita,et al.  Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. , 1997, Circulation.

[27]  H. Drexler,et al.  Endothelial dysfunction: clinical implications. , 1997, Progress in cardiovascular diseases.

[28]  R. Alexander,et al.  Angiotensin II signaling in vascular smooth muscle. New concepts. , 1997, Hypertension.

[29]  K. Pritchard,et al.  Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. , 1996, Circulation research.

[30]  D. Harrison,et al.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. , 1995, The Journal of clinical investigation.